Artiges A
226 avenue de Colmar, BP 907, F67029 Strasbourg Cedex 1, France.
Ann Pharm Fr. 2002 Sep;60(5):333-40.
In April 1994, t he European Pharmacopoeia Commission set up a new procedure for the "Certification of Suitability of Monographs of the European Pharmacopoela" to deal with the changing requirements of the licensing authorities and the growth of international trade, notably as regards raw materials to be used in the manufacture of medicines. This procedure was the result of extensive collaboration between the licensing authorities of the European Union and the other parties to the European Pharmacopoeia Convention, and it enables a manufacturer of a raw material for pharmaceutical use to demonstrate that the purity of their substance is suitably controlled by the monograph of the European Pharmacopoeia; this demonstration is now required by the guideline on "Requirements in Relation to Active Substances" published in Volume 3A of the Rules Governing Medicinal Products in the European Union. Initially set up in response to problems with impurities of synthesis and residual solvents that can vary from one manufacturer to another, the procedure has gradually been extended to a very wide range of products including products of fermentation and, more recently, products with risk of transmitting agents of animal spongiform encephalopathies.
1994年4月,欧洲药典委员会设立了一项新程序,即“欧洲药典各论适用性认证”,以应对药品许可当局不断变化的要求以及国际贸易的增长,特别是在药品生产所用原材料方面。该程序是欧盟药品许可当局与欧洲药典公约其他各方广泛合作的成果,它使药用原材料制造商能够证明其物质的纯度受到欧洲药典各论的适当控制;欧盟药品管理规则第3A卷中发布的“活性物质相关要求”指南现在要求进行这种证明。该程序最初是为应对不同制造商合成杂质和残留溶剂问题而设立的,后来逐渐扩展到非常广泛的产品,包括发酵产品,以及最近具有传播动物海绵状脑病病原体风险的产品。